BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 12394262)

  • 21. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
    Nabholtz JM; Smylie M; Mackey J; Paterson A; Noel D; al-Tweigeri ; Janowska A; Delorme F; Riva A
    Oncology (Williston Park); 1997 Jun; 11(6 Suppl 6):25-7. PubMed ID: 9213324
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of dose-dense doxorubicin and docetaxel as neoadjunvant chemotherapy with G-CSF support in patients with large or locally advanced breast cancer.
    García-Mata J; García-Palomo A; Calvo L; Mel R; Cruz JJ; Ramos M
    Clin Transl Oncol; 2008 Nov; 10(11):739-44. PubMed ID: 19015070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer.
    Polyzos A; Tsavaris N; Kosmas C; Gogas H; Vadiaka M; Markopoulos C; Giannopoulos A; Kalahanis N; Stamatiadis D; Kouraklis G; Karatzas G; Liapis C; Syrigos K
    Anticancer Res; 2003; 23(3C):2917-23. PubMed ID: 12926135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I/II trial of adjuvant dose-dense docetaxel/epirubicin/cyclophosphamide (TEC) in stage II and III breast cancer.
    Burdette-Radoux S; Wood ME; Olin JJ; Laughlin RS; Crocker AM; Ashikaga T; Muss HB
    Breast J; 2007; 13(3):274-80. PubMed ID: 17461902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumours.
    Mitchell PL; Basser R; Chipman M; Grigg A; Cebon J; Davis ID; Zalcberg J; Ng S; Appia F; Green M
    Ann Oncol; 2003 May; 14(5):788-94. PubMed ID: 12702535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
    Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
    J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter phase II study.
    Georgoulias V; Androulakis N; Dimopoulos AM; Kourousis C; Kakolyris S; Papadakis E; Apostolopoulou F; Papadimitriou C; Vossos A; Agelidou M; Heras P; Tzannes S; Vlachonicolis J; Mavromanolakis E; Hatzidaki D
    Ann Oncol; 1998 Mar; 9(3):331-4. PubMed ID: 9602269
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer.
    Kubista E; Glaspy J; Holmes FA; Green MD; Hackett J; Neumann T;
    Clin Breast Cancer; 2003 Feb; 3(6):391-8. PubMed ID: 12636878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of doxorubicin plus cyclophosphamide followed by docetaxel as adjuvant chemotherapy for breast cancer.
    Livi L; Meattini I; de Luca Cardillo C; Scotti V; Agresti B; Franzese C; Sanchez L; Nori J; Bertocci S; Cassani S; Bianchi S; Cataliotti L; Biti G
    J Chemother; 2011 Feb; 23(1):36-9. PubMed ID: 21482493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study.
    Frasci G; Comella P; D'Aiuto G; Budillon A; Barbarulo D; Thomas R; Capasso I; Casaretti R; Daponte A; Caponigro F; Gravina A; Maiorino L; Caratení G; Gentile A; Comella G
    Breast Cancer Res Treat; 1998 May; 49(1):13-26. PubMed ID: 9694607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
    Holmes FA; O'Shaughnessy JA; Vukelja S; Jones SE; Shogan J; Savin M; Glaspy J; Moore M; Meza L; Wiznitzer I; Neumann TA; Hill LR; Liang BC
    J Clin Oncol; 2002 Feb; 20(3):727-31. PubMed ID: 11821454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a phase II study.
    Pectasides D; Visvikis A; Kouloubinis A; Glotsos J; Bountouroglou N; Karvounis N; Ziras N; Athanassiou A
    Eur J Cancer; 2002 Jun; 38(9):1194-200. PubMed ID: 12044505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase II study.
    Frasci G; D'Aiuto G; Comella P; Thomas R; Capasso I; Di Bonito M; Rivellini F; Carteni G; De Lucia L; Maiorino L; D'Aniello R; Frezza P; Lapenta L; Comella G
    Breast Cancer Res Treat; 2000 Jul; 62(2):87-97. PubMed ID: 11016746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
    Valero V
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study.
    Ferraresi V; Milella M; Vaccaro A; D'Ottavio AM; Papaldo P; Nisticò C; Thorel MF; Marsella A; Carpino A; Giannarelli D; Terzoli E; Cognetti F
    Am J Clin Oncol; 2000 Apr; 23(2):132-9. PubMed ID: 10776972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Phase II trial of docetaxel and carboplatin administered every 2 weeks as preoperative therapy for stage II or III breast cancer: NCCTG study N0338.
    Roy V; Pockaj BA; Allred JB; Apsey H; Northfelt DW; Nikcevich D; Mattar B; Perez EA
    Am J Clin Oncol; 2013 Dec; 36(6):540-4. PubMed ID: 22868240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial.
    Mavroudis D; Kourousis C; Androulakis N; Kalbakis K; Agelaki S; Kakolyris S; Souglakos J; Sarra E; Vardakis N; Hatzidaki D; Sarmonis G; Georgoulias V
    Am J Clin Oncol; 2000 Aug; 23(4):341-4. PubMed ID: 10955859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant moderately high-dose chemotherapy with rh-G-CSF in locally advanced breast carcinoma.
    Fornasiero A; Ghiotto C; Daniele O; Favaretto AG; D'Amanzo P; Ziade A
    Tumori; 2001; 87(4):223-8. PubMed ID: 11693799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial.
    Alexopoulos K; Kouroussis C; Androulakis N; Papadakis E; Vaslamatzis M; Kakolyris S; Samelis G; Patila E; Vossos A; Samantas E; Georgoulias V
    Cancer Chemother Pharmacol; 1999; 43(3):257-62. PubMed ID: 9923557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.